PSS18 Economic Burden of Burn Injuries in the Netherlands  by Hop, J.M. et al.
A606  VA L U E  I N  H E A LT H  1 7  ( 2 0 1 4 )  A 3 2 3 – A 6 8 6  
PSS16
CoSt-AnAlySiS of ChroniC idioPAthiC UrtiCAriA diSeASe
Tatar M.1, Senturk A.2, Ergin G.2, Tuna E.2, Mat C.3, Bulbul Baskan E.4, Artuz F.5, Gurer M.A.6, 
Atakan N.7, Inaloz S.8, Sezen S.9, Keskinaslan A.9, Saylan M.9
1Hacettepe University, Ankara, Turkey, 2Polar Polar Health Economics & Policy, Ankara, Turkey, 
3Cerrahpasa Medical Faculty, Istanbul, Turkey, 4Uludag Medical Faculty, Bursa, Turkey, 5Ankara 
Numune research and Training Hosptial, Ankara, Turkey, 6Gazi University Medical Faculty, 
Ankara, Turkey, 7Hacettepe University Faculty of Medicine, Ankara, Turkey, 8Gaziantep University 
Medical Faculty, Gaziantep, Turkey, 9Novartis Pharma, Istanbul, Turkey
Objectives: Chronic idiopathic (or spontaneous) urticaria (CIU) is estimated to 
occur in 0.3% of the general population in Turkey. Although the burden of the dis-
ease is substantial for the payer, there has been no cost-analysis performed in our 
country. The purposes of this study are to determine the resources and costs related 
to the diagnosis and treatment of patients with CIU, and to estimate the annual eco-
nomic burden to the Social Security Institution (SGK). MethOds: Delphi technique 
was applied to determine the type and the amount of resources used in different 
stages of CIU defined as mild or moderate to severe based on physicians clinical 
assessment. The Delphi method solicits the opinion of an expert panel through a 
carefully designed questionnaire which in this case included questions on: epi-
demiology, diagnosis, treatment of symptoms and angioedema, adverse events, 
follow-up visits, hospital and emergency service admissions. The responses were 
analysed and discussed in a face to face meeting followed by consensus building 
steps. Unit of resources used for different CIU severity levels were determined from 
expert opinion. Unit costs of resources used in outpatient clinics were obtained 
from SGK’s Reimbursement Guideline-List of Procedure Fees Per Service. Results: 
Hospitalizations, emergency admissions, outpatient visits and treatments, are the 
key cost drivers in the management of CIU The annual cost per patient is calcu-
lated to be 725.36 Turkish Liras (TL) for mild CIU, 1.322,61 TL for moderate CIU and 
2,478.75 TL for severe CIU. The total annual cost of CIU to SGK is estimated to be 262 
million TL in 2014. cOnclusiOns: This is the first study that aims to estimate the 
resource utilisation and cost burden of CIU in Turkey by using the Delphi technique. 
Cost effective treatment of CIU is an unmet need given the heavy burden to SGK 
identified by the Delphi Panel.
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Objectives: Treatment delays in patients with wAMD and DME are very impor-
tant since they are associated with disease progression. This is the first study in 
Greece to highlight patient’s access delays’ to treatment and to estimate the burden 
of diseases in Greece. MethOds: An expert panel with 11 ophthalmologists was 
convened. The experts came from six out of seven Regional Health Authorities, 
covering geographically the largest part of the country. A 13-page questionnaire 
was developed and validated. The Delphi technique was used to collect data on 
resource use and disease management, patient access delays, and indirect costs. 
Unit costs were retrieved from NHS sources and the analysis was conducted from 
the societal perspective, including direct costs incurred by patients, their families 
and the health care system, and indirect costs, of productivity losses. Results: 
Total cost of managing wAMD during the first year of treatment was estimated at 
€ 20,660,32.8% of which consisted of direct costs (drug acquisition and administra-
tion, follow-up, lab and imaging tests), and 67.2% of which included non-medical 
and indirect costs (caregivers). Direct medical cost per DME patient for the first year 
of treatment was estimated at € 6,066, while the non-medical and indirect costs were 
estimated at € 12,271, resulting in a total cost of € 18,337 per patient per year. 91% of 
the experts agreed that there are significant delays in patient access to specific treat-
ments (average 20 days); all agreed (100%) that these delays lead to faster disease 
progression, and a strong majority (> 80%) supported that they lead to deterioration 
of patients’ QoL. cOnclusiOns: There are significant costs associated with the 
management of wAMD and DME in Greece, 70% of which is incurred by patients and 
their families. Administrative procedures leading to patient access delays should be 
minimized in order to avoid disease progression and associated costs.
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Objectives: Burn care has rapidly improved in the past decades. However, health 
care innovations can be expensive, demanding careful choices on their implementa-
tion. Obtaining knowledge on the extent of the costs of burn injuries is an essential 
first step for economic evaluations within burn care. The objective of this study was 
to determine the economic burden of patients with burns admitted to a burn center 
and to identify important cost categories until three months post-burn. MethOds: 
A prospective cohort study was conducted in the burn center of Maasstad Hospital 
Rotterdam, the Netherlands, including all patients with acute burn related injuries 
from August 2012 until July 2013. Total costs were calculated from a societal perspec-
tive, until three months post injury. Subgroup analyses were performed to examine 
whether the mean total costs per patient differed by age, etiology or percentage 
total body surface area (TBSA) burned. Results: In our population, with a mean 
burn size of 8%, mean total costs were € 24,246 per patient varying from € 11,498 to 
€ 71,756. Most important cost categories were burn center days, surgical interven-
tions and work absence. Flame burns were significantly more costly than other types 
of burns, adult patients were significantly more costly than children and adolescents 
decreased with VI severity (the adjusted difference in LP between participants with 
mild and moderate/severe VI= S$0.22K, P= 0.3846). cOnclusiOns: Visual impair-
ment poses substantial economic burden on individuals and families in Singapore. 
The economic burden of VI is mainly medical costs. Self-reported health problems 
seem to be better predictors of costs of VI than clinical measures.
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Objectives: Burn care is traditionally considered expensive care. However, detailed 
information about the costs of burn care is scarce, despite the increased need for this 
information and the enhanced focus on health care cost control. In this study, eco-
nomic literature on burn care was systematically reviewed to examine the problem 
of burn-related costs. MethOds: Cost or economic evaluation studies on burn care 
that had been published in international peer-reviewed journals from 1950-2012 
were identified. The methodology of these articles was critically appraised by two 
reviewers, and cost results were extracted. Results: A total of 156 studies met the 
inclusion criteria. Nearly all of the studies were cost studies (n= 153) with a health 
care perspective (n= 139) from high income countries (n= 127). Hospital charges were 
often used as a proxy for costs (n= 44). Three studies were cost-effectiveness analy-
ses. The mean total health care cost per burn patient in high-income countries was 
$88,218 (range $704- $717,306, median $44,024). cOnclusiOns: A wide variety of 
methodological approaches and cost prices was found. We recommend that cost 
studies and economic evaluations employ a standard approach to improve the 
quality and harmonization of economic evaluation studies, optimize comparability 
and improve insight into burn care costs and efficiency.
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Objectives: To appraise the literature referred to direct and indirect costs of pso-
riasis in Europe. MethOds: A systematic review of the literature was performed. 
Electronic databases [MedLine/PubMed, Scopus, Cochrane Library, ISI Wok, MEDES, 
IBECS, CSIC] and Google Scholar were searched to identify publications referred 
to direct and indirect costs of psoriasis in Europe. Bibliographic references were 
hand searched. European studies published in English or Spanish until October 
2013 were selected. Economic evaluations of specific drugs and of preventive or 
diagnostic interventions were excluded. Costs were updated to € , 2013. Results: 
12 studies were reviewed (4 German, 2 Swedish, 2 Italian, 1 Dutch, 1 
French, 1 English and 1 Spanish). From the social perspective, the mean 
annual cost of psoriasis in Europe was heterogeneous and varied between 
€ 1,340.25 (Spain) and € 8,253.74 (Italy), mainly due to differences of study 
sample characteristics, methodology used and national health system 
features. The highest proportion (68%-82.5%) of total costs was attribut-
able to direct costs (hospitalizations, medications and laboratory tests). 
The annual total cost of severe psoriasis was, at least, 2.5 fold superior to the costs 
of mild disease, mostly because of a more frequent use of hospital resources and 
loss of productivity. Out-of-pocket expenditure ranged from € 480.67 to € 797.00, 
being mostly explained by the use of dermatological products (OTC) (29%-59.7%) 
and alternative therapies (balnerotherapies) (24%-49%). The initiation of biologic 
therapies implied reductions of up to 76% on the length of hospital stay and up to 
98% hospital admissions, contributing to a decline of inpatient cost [€ 2,357.30 (SD: 
722.29) vs. € 564.19 (SD: 257.62); p= 0.005; UK]. cOnclusiOns: Costs results vary 
across European countries. Severe psoriasis is a costly disease. The use of biologic 
agents may contribute to a more efficient management of severe psoriasis due to 
a more steady control of symptoms that improve clinical outcomes and decrease 
the needs for hospital care and inpatient cost.
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Objectives: To provide a literature overview on the costs of diabetic complications 
focused on the economic burden of Diabetic Macular Edema (DME) and associated 
vision loss and blindness. MethOds: Literature searches in PubMed (including 
Medline) and Embase were conducted to identify economic data related to diabetic 
retinopathy, macular edema, blindness and low vision. Posterior filters included 
year of publication (from 2000 to May 2014), country (Canada, USA or Europe) and 
English language. Relevant full text articles were reviewed and major findings sum-
marized. Results: A total of 468 citations from 5 different searches were retrieved 
and 16 studies fulfilled the criteria to be summarized in this review. Microvascular 
diabetic complications were found to be frequent and led to a 70% increase in 
direct costs compared to patients with no complications. When microvascular and 
macrovascular complications were given together, management costs increased 
by up to 250%. Eye disease was associated with a 2,5 ratio of extra cost compared 
to diabetic patients without complications, with DME incurring in twice to 3 times 
higher costs related to Diabetic Retinopathy. Direct costs of DME accounted for 
65-80% of total costs, with 73% of those being associated to hospital expenditure. 
Data on the economic burden of visual impairment and blindness were limited: 
vision loss had an annual per capita financial cost of $19.370 in Canada (2007); 
including the value of lost wellbeing, the annual cost of vision loss was $33.704 
per patient. cOnclusiOns: DME appears to be a costly complication of diabetes. 
Progression to visual impairment and blindness can lead to high economic and 
social burden.
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while total costs incurred by this population sample were 3,774,256RSD. Highest 
unit utilization of services belongs to conservative dentistry (31.9%), oral surgery 
(19.5%) and radiology (17.4%), while highest value based turnover belongs to implan-
tology 90,765.33±43,012.31RSD, orthodontics 77,361.82±73,123.92RSD and pros-
thetics 60873.89±26788.87RSD. Most frequently treated diagnosis was tooth decay 
(33.8% unit services provided), pulpitis (11.2%) and impacted teeth (8.5%), while 
most expensive to treat were anomalies of tooth position (70,998.33±73122.73RSD), 
abnormalities of size and form of teeth (55,662.50±77,304.45RSD) and loss of teeth 
due to accident, extraction or local periodontal disease (36,835.35±37,128.28RSD). 
cOnclusiOns: Although range of dental medical costs currently falls behind EU 
average, Serbia’s emerging economy is likely to expand in the long run while market 
demand for dental services will grow. Due to threatened financial sustainability of 
current health insurance patterns in Eastern Europe, getting acquainted with true 
size and structure of dental care costs might essentially support informed decision 
making in future.
PSS22
CoSt-effeCtiveneSS AnAlySiS of UStekinUMAb CoMPAred With 
etAnerCePt for the treAtMent of ModerAte to Severe PSoriASiS in 
CoStA riCA
Obando C.A., Desanvicente-Celis Z., Herrera J.A., Moreira M., De Castro J.
Janssen, Panama, Panama
Objectives: To assess the cost-effectiveness of Ustekinumab (UST) com-
pared with Etanercept (ETN) in Costa Rica, in patients with Moderate to Severe 
Psoriasis. MethOds: A cohort simulation Markov Model was developed based on 
response rates for UST and ETN [Psoriasis Area Severity Index (PASI) ]. The time 
frame was 10 years. The perspective was that of the Public System of Health of 
Costa Rica. The health outcome of interest was Quality Adjusted Life Years (QALYs). 
Efficacy data was taken from the ACCEPT clinical trial; this phase III clinical trial 
directly compares UST and ETN, what strongly supports the efficacy data that is 
used in the model. Utilities for health states were taken from published studies. 
The base year was 2013. All costs are presented in Costa Rican currency (Colones – 
CRC). Costs and outcomes were discounted at 3.5%. Probabilistic sensitivity analysis 
(PSA) was conducted to assess uncertainty around the parameters. Results: UST 
resulted in 3.85 QALYs and ETN in 3.58, per patient, respectively. Mean total costs 
per patient were: CRC 8.441.031 for UST and CRC 5.401.222 for ETN. UST resulted 
both more costly and more effective than ETN. The Incremental Cost Effectiveness 
Ratio comparing UST and ETN was 11.142.470 per QALY Gained. According to the 
classification of the World Health Organization (WHO), the acceptable threshold for 
QALY Gained for Costa Rica is CRC 14.140.792 (3 times the Gross Domestic Product 
per capita). The results of the probabilistic sensitivity analysis showed that, at the 
threshold suggested by the WHO, the probability of UST of being cost effective, 
compared with ETN is around 70%. cOnclusiOns: UST can be considered cost 
effective when compared to ETN, according to the threshold suggested by the WHO, 
in patients with moderate to severe Psoriasis, from the perspective of the Public 
System of Health of Costa Rica.
PSS23
CoSt-effeCtiveneSS of rAnibizUMAb on PAtientS With diffUSe 
diAbetiC MACUlAr edeMA Within the PUbliC MexiCAn heAlth CAre 
SySteM
Ruiz Miranda C.I., Ubiarco Lopez V.
Novartis Mexico, Mexico, Mexico
Objectives: To perform a cost-effectiveness analysis of Ranibizumab plus laser 
photocoagulation vs monotherapy with laser photocoagulation in patients with 
diffuse Diabetic Macular Edema (DME). MethOds: A Markov model was designed 
to analyze laser Photocoagulation vs laser Photocoagulation plus Ranibizumab. 
Transition probabilities were obtained from RESTORE. The base patient was a dia-
betic with 53 years presenting DME, according to Mexican context. General mortality 
rates were elicited locally from CONAPO*. A panel Delphi was performed to get use 
of resources locally. The time horizon was 5, 7, and 10 (lifetime) years according 
to life expectancy from ENSANUT** 2013, discount rate 5%. The outcome was life 
years without visual impairment. The cost values were from Guidelines for the 
Exchange of Services in the Health Sector. Probabilistic sensitivity analysis (PSA) was 
performed using Monte Carlo technique. Results: Incremental Cost Effectiveness 
Ratios of the combination versus the monotherapy were: $5,019.57, $2,375.62 and 
$622.67 USD per life year without visual impairment in a time horizon of 5, 7 years 
and lifetime. Cost effectiveness curve showed Ranibizumab be a cost effective 
option at 98.7% vs monotherapy before reaching the GDP per capita. cOnclusiOns: 
Ranibizumab demonstrated to be a more cost-effectiveness alternative than mono-
therapy with laser photocoagulation. These results show the possibility of achiev-
ing potential clinical benefit with Ranibizumab in patients suffering from loss of 
vision. *CONAPO National Council of Population **ENSANUT National Health and 
Nutrition Survey
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Objectives: Like other North African countries, Tunisia has a substantial burden of 
pneumococcal disease, with high resistance to antibiotics. The Tunisian population 
remains largely unprotected in the absence of a national immunization program 
(NIP). MethOds: A decision-analytic model was developed to evaluate the potential 
outcomes and costs of the PCV13-based NIP compared to no vaccination. The model 
estimates bacteremia and meningitis (jointly IPD), all-cause community acquired 
pneumonia (CAP), and all-cause otitis media (OM). The demographics and disease 
and a higher percentage TBSA burned also corresponded to significantly higher 
costs. cOnclusiOns: Mean total costs of burn care in the first three months post 
injury were estimated at € 24,246 and depended on age, etiology and TBSA. Mean 
total costs in our population probably apply for other high-income countries as well, 
although we should realize that patients with burn injuries are diverse and repre-
sent a broad range of total costs. To reduce costs of burn care, future intervention 
studies should focus on reducing length of stay and enabling an early return to work.
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Objectives: Aims The aim of this study is to estimate the prevalence of blind-
ness in the Republic of Ireland and estimate the financial and economic cost of 
blindness between 2010 and 2020. MethOds: The prevalence of blindness was 
based on the National Council for the Blind of Ireland blind register and adjusted 
for under registration found in previous literature. The financial cost of blind-
ness was based on the sum of total direct and indirect health care costs (direct 
health care costs due to blindness, cost of depression due to blindness, cost of 
injurious falls due to blindness) and non-health care costs (productivity losses, 
informal care and deadweight welfare loss). Where possible, methods adopted 
reflect those used elsewhere in the literature. Results: The total financial cost 
of blindness in the ROI is estimated to have been € 276. million in 2010. This is 
projected to increase by 32.6% to € 367 million in 2020 if current trends in disease 
burden continue. The total economic cost of blindness in the ROI is estimated to 
be € 809 million in 2010 and is predicted to increase to over € 1.1 billion in 2020 
based on current trends. cOnclusiOns: A significant proportion of blindness 
can be avoided through the implementation of existing technologies by the 
health service. However a significant portion (98.04%) of the burden of illness 
falls beyond the health service (primarily to the Department of Social Protection 
and the Department of Finance) and may serve to reducethe priority of policies 
aimed at avoiding blindness that might otherwise be received.
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Cost-of-illness study of senile cataract in the Czech RepublicIlona Kruntorádová, 
Klára Kruntorádová, Vladimír Rogalewicz, Miroslav Barták. Objectives: In the 
Czech Republic, 7% of patients with senile cataract are indicated for surgery each 
year, which means ten thousand of interventions annually. The aim of this study 
is to quantify direct costs in relation to the implanted intraocular lens type from 
both the public health insurance perspective and the patient’s perspective. The 
senile cataract surgery with monofocal IOL is covered by public health insur-
ance. MethOds: Direct costs were calculated through a panel of experts that pro-
vided expert opinions, taking into account consumption of paid medical services 
provided to patients. The panel consisted of 6 experts (4 physicians from eye clinics, 
2 physicians from outpatient departments). Patient´s costs were obtained through 
a patient questionnaire asking the direct (out-of-pocket) expenses associated with 
the cataract. The study covered a cohort of 200 patients with senile cataract in 
non-productive age (65+). Data were collected from 4 clinics performing cataract 
surgery. Results: The structure of direct costs associated with senile cataract, 
its surgery, and treatment of possible complications has been specified. Direct 
costs of senile cataract surgery from the perspective of public health insurance 
are CZK24900 (»EUR907) per person. Patient´s direct costs are lower for monofocal 
lenses than for multifocal ones. Patients’ costs for an IOL and the related treatment 
reach up to CZK35000 (»EUR1275), out of pocket expenses after treatment average 
out at CZK4450 (»EUR162). cOnclusiOns: Due to absence of laws governing medi-
cal care premium services and the age of patients, monofocal IOLs are implanted 
predominantly. As a consequence, up to CZK 30 million (»EUR 1 1 million) are saved 
on the public health insurance budget annually. Patients´ expenses for implanting 
multifocal lenses are offset by savings due to unrealized spending for eyeglasses 
and related medical care in the course of time.
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Objectives: Dental medical care bears particular financial burden for Eastern 
European transitional economies due to its lack of insurance coverage in most 
countries of the region and almost complete out-of-pocket payments by citizens. 
This study estimates real costs of these services in the field and describe resource 
use patterns and differentials across clinical dentistry branches, ICD-10 diagnostic 
groups, and across particular medical services. MethOds: In a case-series design 
prospective cost-comparison study has been conducted from the perspective of 
the patient. Sample size was 752 complete episodes of treatment, selected ran-
domly in 2012/2013 throughout an array of several specialist state-owned (university 
associated) and private-owned dental clinics in upper-middle income Serbia. All 
direct medical costs of dental care were taken into account. Costs were expressed 
in national currency Republican Serbian Dinar (RSD). Results: Mean total direct 
medical costs of dental care were 5,018.96±17,109.61RSD per single dentist visit 
